# China Pharma Holdings, Inc.: overview CPHI · NYSE · CIK 1106644 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cphi.md) · [Financials](/companies/cphi/financials.md) · [Filings](/companies/cphi/filings.md) · [Insiders](/companies/cphi/insiders.md) Latest reported revenue: [$948.3k](/filings/0001213900-26-090173.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-090173). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,100](/filings/0001213900-25-109203.md) | [1,134 d](/filings/0001213900-26-038521.md) | [1,136](/filings/0001213900-26-057705.md) | [1,026](/filings/0001213900-26-090173.md) | [756](/filings/0001213900-25-109203.md) | [1,226 d](/filings/0001213900-26-038521.md) | [984](/filings/0001213900-26-057705.md) | [948](/filings/0001213900-26-090173.md) | | Gross margin | % | [(47.2%)](/filings/0001213900-25-109203.md) | [(14.2%) d](/filings/0001213900-26-038521.md) | [(12.0%)](/filings/0001213900-26-057705.md) | [(8.5%)](/filings/0001213900-26-090173.md) | [(7.9%)](/filings/0001213900-25-109203.md) | [12.3% d](/filings/0001213900-26-038521.md) | [29.0%](/filings/0001213900-26-057705.md) | [8.8%](/filings/0001213900-26-090173.md) | | Operating margin | % | [(98.6%)](/filings/0001213900-25-109203.md) | [(105.5%) d](/filings/0001213900-26-038521.md) | [(66.8%)](/filings/0001213900-26-057705.md) | [(63.6%)](/filings/0001213900-26-090173.md) | [(83.1%)](/filings/0001213900-25-109203.md) | [(97.9%) d](/filings/0001213900-26-038521.md) | [(113.6%)](/filings/0001213900-26-057705.md) | [(151.0%)](/filings/0001213900-26-090173.md) | | Net margin | % | [(101.6%)](/filings/0001213900-25-109203.md) | [(108.0%) d](/filings/0001213900-26-038521.md) | [(69.1%)](/filings/0001213900-26-090173.md) | [(51.5%)](/filings/0001213900-26-090173.md) | [(86.2%)](/filings/0001213900-25-109203.md) | [(99.7%) d](/filings/0001213900-26-038521.md) | [(116.2%)](/filings/0001213900-26-090173.md) | [(153.8%)](/filings/0001213900-26-090173.md) | | Diluted EPS | $ per share | [(0.65)](/filings/0001213900-25-109203.md) | not reported | [(0.24)](/filings/0001213900-26-057705.md) | [(0.16)](/filings/0001213900-26-090173.md) | [(0.17)](/filings/0001213900-25-109203.md) | not reported | [(0.04)](/filings/0001213900-26-057705.md) | [(0.04)](/filings/0001213900-26-090173.md) | | Free cash flow | $k | [(56.2) d](/filings/0001213900-25-109203.md) | [279 d](/filings/0001213900-26-038521.md) | [(132)](/filings/0001213900-26-057705.md) | [274 d](/filings/0001213900-26-090173.md) | [(205) d](/filings/0001213900-25-109203.md) | [152 d](/filings/0001213900-26-038521.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [9,642](/filings/0001213900-23-024710.md) | [8,104](/filings/0001213900-24-028731.md) | [7,011](/filings/0001213900-25-026280.md) | [4,529](/filings/0001213900-26-038521.md) | [4,144](/filings/0001213900-26-038521.md) | | Gross margin | % | [3.6%](/filings/0001213900-23-024710.md) | [(6.1%)](/filings/0001213900-24-028731.md) | [(4.0%)](/filings/0001213900-25-026280.md) | [(43.8%)](/filings/0001213900-26-038521.md) | [(3.2%)](/filings/0001213900-26-038521.md) | | Operating margin | % | [(29.7%)](/filings/0001213900-23-024710.md) | [(43.8%)](/filings/0001213900-24-028731.md) | [(39.2%)](/filings/0001213900-25-026280.md) | [(101.3%)](/filings/0001213900-26-038521.md) | [(78.2%)](/filings/0001213900-26-038521.md) | | Net margin | % | [(35.3%)](/filings/0001213900-23-024710.md) | [(49.0%)](/filings/0001213900-24-028731.md) | [(43.9%)](/filings/0001213900-25-026280.md) | [(104.6%)](/filings/0001213900-26-038521.md) | [(76.9%)](/filings/0001213900-26-038521.md) | | Diluted EPS | $ per share | [(0.74)](/filings/0001213900-23-024710.md) | [(3.78)](/filings/0001213900-24-028731.md) | [(0.91)](/filings/0001213900-25-026280.md) | [(2.71)](/filings/0001213900-26-038521.md) | [(0.74)](/filings/0001213900-26-038521.md) | | Free cash flow | $k | [(688)](/filings/0001213900-23-024710.md) | [(812)](/filings/0001213900-24-028731.md) | [(711)](/filings/0001213900-25-026280.md) | [(444)](/filings/0001213900-26-038521.md) | [88.9](/filings/0001213900-26-038521.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cphi/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $82.8k | 125,445 | | Added +112,521 | | [TWO SIGMA SECURITIES, LLC](/funds/1450144.md) | 2026-06-30 | $23.5k | 35,666 | | New +35,666 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $9.9k | 15,045 | | Added +3,627 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $9.2k | 13,886 | | New +13,886 | | [Ground Swell Capital, LLC](/funds/1534450.md) | 2026-06-30 | $7.0k | 10,610 | | New +10,610 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $2.1k | 3,109 | | Added +2,720 | | [EFG International AG](/funds/2109868.md) | 2026-06-30 | $26 | 40 | | Unchanged | | [DANSKE BANK A/S](/funds/800177.md) | 2026-06-30 | $1 | 1 | | Unchanged | ## Recent filings [All 283 filings](/companies/cphi/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-14 | 16:32 ET | [10-Q](/filings/0001213900-26-090173.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090173 | | 2026-07-22 | 17:26 ET | [8-K](/filings/0001213900-26-080475.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-080475 | | 2026-05-15 | 16:05 ET | [10-Q](/filings/0001213900-26-057705.md) | Quarterly report, period 2026-03-31 | 0001213900-26-057705 | | 2026-04-01 | 16:15 ET | [10-K](/filings/0001213900-26-038521.md) | Annual report, period 2025-12-31 | 0001213900-26-038521 | | 2026-03-03 | 16:05 ET | [8-K](/filings/0001213900-26-023022.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-023022 | | 2026-02-10 | 16:49 ET | [8-K](/filings/0001213900-26-014338.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-014338 | | 2026-01-06 | 16:05 ET | [8-K](/filings/0001213900-26-001785.md) | 5.07 Shareholder vote results | 0001213900-26-001785 | | 2025-12-23 | 16:05 ET | [8-K](/filings/0001213900-25-125299.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity | 0001213900-25-125299 | | 2025-12-10 | 16:49 ET | [8-K](/filings/0001213900-25-120129.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity | 0001213900-25-120129 | | 2025-11-14 | 16:22 ET | [DEF 14A](/filings/0001213900-25-110882.md) | Proxy statement, period 2025-12-30 | 0001213900-25-110882 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-038521.md), filed Apr 1, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/643b7b0c-4026-4873-a8b2-e683d74db384) ## About the filer - CIK: 1106644 - Tickers: CPHI - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.